Aytu Bioscience Inc (NASDAQ:AYTU)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Thursday. They presently have a $9.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 176.07% from the stock’s previous close.

Separately, Rodman & Renshaw assumed coverage on shares of Aytu Bioscience in a research report on Monday, September 26th. They issued a “buy” rating and a $9.00 price target on the stock.

Aytu Bioscience (NASDAQ:AYTU) opened at 3.26 on Thursday. The firm’s 50-day moving average is $3.62 and its 200 day moving average is $4.76. Aytu Bioscience has a 52-week low of $3.01 and a 52-week high of $57.00. The stock’s market capitalization is $16.53 million.

Aytu Bioscience Company Profile

Aytu Bioscience, Inc, formerly Rosewind Corporation, is a healthcare company. The Company is focused on developing treatments for urological and related conditions. The Company’s pipeline of products includes Zertane, and Zertane and a phosphodiesterase type 5 (PDE-5). The Company is conducting Phase III clinical development for its lead therapeutic candidate Zertane, an orally disintegrating tablet (ODT) formulated for the treatment of premature ejaculation (PE).

5 Day Chart for NASDAQ:AYTU

Receive News & Stock Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related stocks with our FREE daily email newsletter.